Hikma Pharmaceuticals PLC (LON:HIK)

Market Cap	3.96B
Revenue (ttm)	2.35B
Net Income (ttm)	270.79M
Shares Out	221.45M
EPS (ttm)	1.22
PE Ratio	14.69
Forward PE	10.12
Dividend	0.59 (3.26%)
Ex-Dividend Date	Aug 14, 2025

Volume	769,981
Average Volume	624,582
Open	1,799.00
Previous Close	1,811.00
Day's Range	1,777.00 - 1,810.00
52-Week Range	1,690.00 - 2,360.00
Beta	0.66
RSI	34.00
Earnings Date	Aug 7, 2025

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 9,500
• Stock Exchange: London Stock Exchange
• Ticker Symbol: HIK

Financial Performance

In 2024, Hikma Pharmaceuticals's revenue was $3.13 billion, an increase of 8.77% compared to the previous year's $2.88 billion. Earnings were $359.00 million, an increase of 88.95%.

Financial numbers in USD